Sale!

CRELD1 Gene Atrioventricular Septal Defect Partial with Heterotaxy Syndrome NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The CRELD1 Gene Atrioventricular Septal Defect Partial with Heterotaxy Syndrome NGS Genetic DNA Test is a specialized diagnostic tool that identifies mutations in the CRELD1 gene associated with congenital heart defects and organ positioning abnormalities. This comprehensive test utilizes next-generation sequencing technology to detect genetic variations that cause partial atrioventricular septal defects combined with heterotaxy syndrome, a condition affecting organ placement. Early genetic identification helps guide surgical planning, medical management, and family counseling. The test is priced at $500 USD (discounted from $700) and provides results within 3-4 weeks using blood, extracted DNA, or FTA card samples. Genetic counseling is recommended before testing to assess family history and inheritance patterns.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

CRELD1 Gene Atrioventricular Septal Defect Partial with Heterotaxy Syndrome NGS Genetic DNA Test

Comprehensive Genetic Analysis for Congenital Heart and Organ Positioning Disorders

The CRELD1 Gene Atrioventricular Septal Defect Partial with Heterotaxy Syndrome NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying genetic mutations responsible for complex congenital conditions affecting heart development and organ positioning. This specialized test provides crucial insights for families and healthcare providers managing these challenging medical conditions.

What This Advanced Genetic Test Detects

This comprehensive NGS-based DNA test specifically targets mutations in the CRELD1 (Cysteine-Rich with EGF-Like Domains 1) gene, which plays a critical role in cardiac development and left-right patterning during embryonic growth. The test identifies:

  • Pathogenic variants in the CRELD1 gene associated with partial atrioventricular septal defects
  • Genetic mutations linked to heterotaxy syndrome manifestations
  • Inheritance patterns for family planning considerations
  • Specific nucleotide changes affecting protein function

Clinical Indications: Who Should Consider Testing

This genetic test is particularly recommended for individuals presenting with:

  • Newborns or children diagnosed with partial atrioventricular septal defects
  • Patients exhibiting heterotaxy syndrome features including abnormal organ positioning
  • Individuals with family history of congenital heart defects or heterotaxy
  • Cases where standard cardiac evaluations suggest genetic involvement
  • Patients undergoing pre-surgical evaluation for complex cardiac repairs

Key Benefits of Early Genetic Identification

Undergoing CRELD1 genetic testing provides numerous advantages for patients and families:

  • Personalized Treatment Planning: Genetic results help tailor surgical approaches and medical management strategies
  • Family Risk Assessment: Identifies inheritance patterns for genetic counseling and family planning
  • Early Intervention Opportunities: Enables proactive monitoring for associated complications
  • Comprehensive Care Coordination: Facilitates multidisciplinary team management
  • Psychological Support: Provides clarity and reduces diagnostic uncertainty

Understanding Your Test Results

Our genetic specialists provide comprehensive interpretation of your CRELD1 test results:

  • Positive Result: Indicates a pathogenic mutation in the CRELD1 gene, confirming genetic diagnosis and enabling targeted management
  • Negative Result: Suggests no detectable CRELD1 mutation, though other genetic factors may still be involved
  • Variant of Uncertain Significance: Identifies genetic changes requiring further research and clinical correlation
  • Carrier Status: Determines inheritance risk for future generations

All results include detailed explanations and recommendations for next steps in consultation with your healthcare team.

Test Specifications and Pricing

Test Component Details
Test Name CRELD1 Gene Atrioventricular Septal Defect Partial with Heterotaxy Syndrome NGS Genetic DNA Test
Regular Price $700 USD
Discount Price $500 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Pre-Test Preparation Requirements

To ensure optimal testing outcomes, we recommend:

  • Complete clinical history documentation of the patient
  • Genetic counseling session to assess family inheritance patterns
  • Development of detailed pedigree chart documenting affected family members
  • Discussion of testing implications and potential outcomes
  • Coordination with referring physician for comprehensive care planning

Nationwide Testing Accessibility

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our network ensures accessible genetic testing services regardless of your location.

Take the Next Step Toward Genetic Clarity

Don’t let uncertainty about genetic conditions affect your family’s future. Our specialized CRELD1 genetic testing provides the answers you need for informed medical decisions and comprehensive care planning. Our experienced genetic counselors and medical professionals are ready to support you through every step of the testing process.

Book your CRELD1 genetic test today or call our dedicated genetic specialists at +1(267) 388-9828 for immediate consultation and scheduling. Take control of your genetic health with confidence and clarity.